Translational science
Experience across immunology, oncology and translational medicine, with attention to how scientific questions move from discovery toward clinical relevance.
Principal
Dr. Rogier Reijmers
Immunologist · Translational Scientist · AI Evaluation Advisor
Founder of TranslAItion Partners, helping biotech and pharma leaders evaluate AI vendors, R&D opportunities and implementation risks through an independent scientific lens.
- 20+ years life-science expertise
- Independent of AI vendors
- Focused on scientific outcomes
Profile
Scientific judgment for AI decisions in biotech and pharma.
Dr. Rogier Reijmers founded TranslAItion Partners to help life-science organizations make better AI decisions before committing budget, data access and internal R&D capacity. His work sits at the intersection of translational science, technology evaluation and practical decision support.
The focus is not AI hype or generic digital transformation. It is whether an AI platform, vendor or use case can create meaningful scientific value in a specific therapeutic, data and organizational context.
Expertise
Relevant experience for evaluating AI in life sciences.
Scientific due diligence
Evaluation of claims, evidence, assumptions and risks before teams commit to technologies, pilots or partnerships.
AI vendor evaluation
Independent assessment of AI platforms against scientific validity, data readiness, workflow fit, adoption friction and cost-to-outcome value.
Evaluation lens
How Rogier reviews AI opportunities and vendors.
AI decisions in biotech and pharma need more than a software comparison. They need scientific, operational and commercial judgment in the same frame.
Science
Does the claim make biological and translational sense, and is the evidence strong enough for the decision being made?
Data
Does the organization have the right data quality, governance, structure and context for the platform to perform?
Implementation
What will it take to embed the tool into real R&D workflows, teams and decision processes?
Outcome
What measurable scientific or strategic value should justify the cost, effort and risk?
Background
A profile built around scientific credibility and independence.
Science
PhD in Immunology
Rogier brings more than two decades of life-science experience, with a background in immunology, oncology and translational research.
Context
Academic and industry environments
His background includes work across academic medical centers and industry life-science settings, with exposure to cross-disciplinary research and evaluation contexts.
Review
Technology and evidence evaluation
TranslAItion Partners applies that scientific review mindset to AI decisions: what is proven, what is assumed, what is missing and what matters for the organization.
Why independence matters
The evaluator should not benefit from the vendor decision.
TranslAItion Partners does not sell AI platforms, resell software or earn vendor referral fees. Recommendations are based on evidence, fit, expected value and decision risk, not on implementation revenue or platform commissions.
No vendor affiliation
AI vendors are assessed from the buyer's scientific and operational context, not from a partner channel.
No implementation dependency
The advice does not depend on selling a follow-on build or integration project.
No generic AI playbook
Each recommendation is tied to the therapeutic question, data reality and team adoption path.
Verification links
Verified profile and publication links.
This profile is intentionally conservative. Confirmed external links are listed here to help visitors and search engines connect Dr. Rogier Reijmers to his professional background.
- LinkedIn profile for Dr. Rogier Reijmers
- ORCID record for Rogier Reijmers
- Google Scholar profile for Rogier M. Reijmers
- ResearchGate profile for Rogier Reijmers
Selected publications can be highlighted separately when Rogier confirms which papers are most representative for the profile.
Discuss an AI decision with Rogier
Share the AI vendor, platform category or R&D opportunity you are evaluating with an independent scientific advisor.
All conversations are confidential. We respond within 24 hours.